We are live on ! Find out more
NBSE

NeuBase Therapeutics, Inc. Common Stock
NBSE

Delisted

NBSE was delisted on the 10th of May, 2024.

Back to rankings

47 hedge funds and large institutions have $9.3M invested in NeuBase Therapeutics, Inc. Common Stock in 2016 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 6 increasing their positions, 15 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

3% less capital invested

Capital invested by funds: $9.56M → $9.3M (-$263K)

8% less funds holding

Funds holding: 51 → 47 (-4)

60% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 15

67% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 6

75% less call options, than puts

Call options by funds: $236K | Put options by funds: $931K

Holders
47
Holders Change
-4
Holders Change %
-7.84%
% of All Funds
1.25%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
6
Reduced
15
Closed
6
Calls
$236K
Puts
$931K
Net Calls
-$695K
Net Calls Change
-$106K

Top Buyers

1
Renaissance Technologies
Renaissance Technologies
New York
+$77.7K
2
Janney Montgomery Scott
Janney Montgomery Scott
Pennsylvania
+$32.4K
3
BA
BlackRock Advisors
Delaware
+$15.1K
4
Group One Trading
Group One Trading
Illinois
+$14K
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$7.55K

Top Sellers

1
ARTA
A.R.T. Advisors
New York
-$155K
2
GCP
GSA Capital Partners
United Kingdom
-$144K
3
Bank of New York Mellon
Bank of New York Mellon
New York
-$64.7K
4
Citadel Advisors
Citadel Advisors
Florida
-$52.9K
5
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
-$48.5K
Name Holding Trade Value Shares
Change 		Change in
Stake
WMC
26
Westwood Management Corporation
Illinois
$57K – – –
Deutsche Bank
27
Deutsche Bank
Germany
$56K -$5.39K -5 -9%
UBS Group
28
UBS Group
Switzerland
$48K +$5.39K +5 +14%
Citadel Advisors
29
Citadel Advisors
Florida
$45K -$52.9K -49 -56%
CG
30
Cutler Group
California
$45K -$23.7K -22 -35%
Janney Montgomery Scott
31
Janney Montgomery Scott
Pennsylvania
$34K +$32.4K +30 New
Creative Planning
32
Creative Planning
Kansas
$33K – – –
State Street
33
State Street
Massachusetts
$30K – – –
WSFS
34
Wilmington Savings Fund Society
Delaware
$28K – – –
BA
35
BlackRock Advisors
Delaware
$26K +$15.1K +14 +156%
First Manhattan
36
First Manhattan
New York
$20K – – –
AIM
37
Acrospire Investment Management
Illinois
$18K -$21.6K -20 -56%
Morgan Stanley
38
Morgan Stanley
New York
$16K +$1.08K +1 +8%
BIM
39
BlackRock Investment Management
Delaware
$13K – – –
CLOS
40
Compagnie Lombard Odier SCmA
Switzerland
$11K – – –
WA
41
WFG Advisors
Texas
$11K – – –
Bank of Montreal
42
Bank of Montreal
Ontario, Canada
$7K -$7.55K -7 -54%
Simplex Trading
43
Simplex Trading
Illinois
$5K -$11.9K -11 -69%
Royal Bank of Canada
44
Royal Bank of Canada
Ontario, Canada
$3K -$48.5K -45 -94%
IA
45
IFP Advisors
Florida
$2K – – –
PCA
46
Peddock Capital Advisors
Massachusetts
$2K +$1.08K +1 New
Bank of America
47
Bank of America
North Carolina
$1K – – –
ARTA
48
A.R.T. Advisors
New York
– -$155K -142 Closed
GCP
49
GSA Capital Partners
United Kingdom
– -$144K -132 Closed
Invesco
50
Invesco
Georgia
– -$43K -39 Closed
1
2
3

NBSE Hedge Fund Activity: Q3 2016 in Review

47 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in NeuBase Therapeutics, Inc. Common Stock (NBSE) for Q3 2016, worth a combined $9.3M — down 2.7% from $9.56M a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of NBSE and 2 opened new positions — a net loss of 4 holders — while 15 trimmed existing stakes and 6 added.

The largest buyer was Renaissance Technologies, adding an estimated $77.7K. The largest seller was A.R.T. Advisors, exiting entirely with an estimated $155K sold.

  • 47 institutional investors held NeuBase Therapeutics, Inc. Common Stock (NBSE) as of Q3 2016, down from 51 in Q2 2016.
  • Funds reported $9.3M of NeuBase Therapeutics, Inc. Common Stock stock for Q3 2016, down 2.7% quarter-over-quarter.
  • 2 funds opened new NeuBase Therapeutics, Inc. Common Stock positions in Q3 2016 and 6 closed out, a net change of -4 holders.
  • The largest NeuBase Therapeutics, Inc. Common Stock buyer in Q3 2016 was Renaissance Technologies, an estimated $77.7K added.
  • The largest NeuBase Therapeutics, Inc. Common Stock seller in Q3 2016 was A.R.T. Advisors, an estimated $155K sold.

Based on aggregated 13F filings for Q3 2016.